TheProductLawyers.com reports on the information released by the U.S. Food and Drug Administration in reference to Invokana and Invokamet, type-2 diabetes drugs. The FDA has received many adverse event reports on the topic. Allegedly the drugs can reduce the bone density of the users and there is an increased risk of injury from bone fractures.
The warning label had noted bone fracture risk but the FDA required changes to the warnings so they would indicate bone fracture seemed to appear more frequently among patients taking Invokana than when compared to those taking only the placebo pills. The FDA noted that fractures from low trauma, such as falling from heights no higher than standing height, were noted as early as 12 weeks after initiating treatment.
According to the new information, fractures can occur easily for patients taking an SGLT2 inhibitor drug. The FDA mentioned a significant decrease in the patient's bone mineral density when they use the drug. The FDA drew attention to a study of 714 elderly patients, where some took Invokana while some did not. Those taking the drug showed increased bone loss within their hips and spine.
The FDA has closely monitored and studied the topic for several years due to the connection to increased bone loss. A public warning regarding bone fractures that were reported to be observed in the 2013 clinical trials was released by the Endocrinologic and Metabolic Drugs Advisory Committee.
Attorneys at Banville understand the seriousness of the health conditions that have recently been connected to SGLT2 inhibitor class drugs. They are currently working to ensure that all patients who have taken or are taking Invokana or another SGLT2 inhibitor class drug and have suffered adverse health events have an opportunity to explore all their legal rights in full. They are also offering complimentary Invokana consultations to individuals interested in seeking justice. Affected parties may be entitled to financial compensation.
For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792
Sponsored by an alliance of attorneys, ZofranLegal.com is a resource for parents, families and birth defect survivors interested in learning more about litigation surrounding the nausea drug Zofran and its link to increased risks of major birth defects.
1368 Barrowdale Road, Rydal, PA 19046
April 30, 2016 – Lawsuit Alleges Invokana Side Effects Can Include Diabetic Ketoacidosis, a Life-Threatening Condition Related to Too Much Acid in the Body
April 29, 2016 – Zofran Lawsuit Update: Plaintiffs Question Why GSK Hasn’t Faced Stiffer Penalties
April 27, 2016 – Arkansas Mother Files Zofran Lawsuit Claiming Multiple Defects Caused By Drug
April 25, 2016 – Zofran Lawsuit Plaintiffs Applaud FDA’s Decision Regarding Folic Acid
April 22, 2016 – MyFoxBoston News Release Discusses Concerning Zofran Birth Defect Lawsuits And Drug Safety
April 22, 2016 – Zofran Lawsuit Plaintiffs Note Results Of Japanese Animal Studies Linking Birth Defects To Drug
April 22, 2016 – A Look Back At America’s First Zofran Lawsuit
April 21, 2016 – Significant Increase In Birth Defect Development Investigated By Washington State Amid Mounting Zofran Lawsuits
April 21, 2016 – Zofran Lawsuit Plaintiffs Make Note Of Canadian Label Differences On Drug Which Warn Of Use During Pregnancy
April 20, 2016 – Zofran Lawsuit Plaintiff Claims Infant’s Cleft Palate, Clubfoot, And Respiratory Distress Caused By Drug Exposure
